CORALVILLE, Iowa, Dec. 3, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Oppenheimer 26th Annual Healthcare Conference being held in New York, NY, on December 8-9, 2015.
Details of KemPharm’s presentation are as follows:
| Date: | Tuesday, December 8, 2015 |
| Time: | 4:30 PM (ET) |
| Location: | Westin Grand Central Hotel in New York, NY |
The presentation will be webcast and available using the conference webcast link at http://www.veracast.com/webcasts/opco/healthcare2015/19115169233.cfm, or on the Investor Relations section of the Company’s website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
CONTACT: For KemPharm, Inc.: Gordon K. “Rusty” Johnson 321-939-3416 info@kempharm.com Media / Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com
